用GameLoop模拟器在電腦上玩IBM Micromedex IV Comp.

IBM Micromedex IV Comp. 電腦版

來自發行商 Mobile Micromedex 的 IBM Micromedex IV Comp. 能夠在安卓系統上運行。

現在，您可以在電腦上使用 GameLoop 模擬器流暢地玩 IBM Micromedex IV Comp.。

在 GameLoop 遊戲庫或搜索結果中下載。 不需要再暢玩遊戲時盯著電池電量或被令人懊惱的來電打斷。

只需在電腦大屏幕上免費下載暢玩IBM Micromedex IV Comp. 電腦版！

IBM Micromedex IV Comp. 簡介

When multiple IV medications are combined, the risk of complication is very real. Efficacy of one or more drugs can be reduced or a potentially dangerous incompatibility can occur. With this app you will have access to the largest, most comprehensive IV compatibility resource which:

• Enhances patient safety by pinpointing potentially dangerous combinations

• Helps clinicians interpret conflicting compatibility results by identifying contributing factors such as the physical compatibility, storage, study period, container and chemical stability

• Includes drug-solution compatibility results as well as drug-drug compatibility results when creating an admixture or administering via Y-Site.

IBM Micromedex IV Comp. is a reliable resource for on-the-go access to the industry’s most trusted clinical reference information, providing users with more informed treatment decisions at the point of care. An internet connection is not required, allowing you to make decisions with confidence at anytime, from anywhere.

Not sure if your institution subscribes to IBM Micromedex? Check with your Chief Medical Officer, Director of Pharmacy, Medical Librarian, or anyone else at your facility responsible for clinical reference information.

If the facility you work at subscribes to Micromedex, follow these instructions to obtain a password:

1. Login to IBM Micromedex through your subscribing facility

2. Click “Download Center” near the top of the application

3. Refer to the detailed downloading instructions, which include your password for activating the application at no charge.

If you cannot locate the “Download Center” link please contact support to receive your password at https://www.ibm.com/support/home/pages/support-guide/?product=4592217

Existing paid customers will continue to have access to the content going forward.